NCT03228277已完成2 期
Phase II, Multicenter, Single-arm, Open-label Study to Evaluate the Efficacy of Olmutinib(Olita®) in Patients With NSCLC Who Harboring T790M Mutation Confirmed Using DNA Extracted From Extracellular Vesicles in Bronchoalveolar Lavage Fluid
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 25
- 试验地点
- 1
- 主要终点
- Objective response rate (ORR)
研究概览
简要总结
The purpose of this study is to evaluate the efficacy of Olmutinib(Olita®) in patients with T790M-positive non-small cell lung cancer (NSCLC) confirmed using DNA extracted from extracellular vesicles of bronchoalveolar lavage fluid.
详细描述
This is a single-arm, open-label, Phase 2 study to assess the anti-tumor efficacy of Olmutinib(Olita®) administered to patients with T790M-positive NSCLC confirmed using DNA extracted from extracellular vesicles in bronchoalveolar lavage fluid as measured by objective response rate (ORR).
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 19 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female, aged at least 19 years
- •Obtained written informed consent
- •Histologically- or cytologically confirmed diagnosis of unresectable Stage IIIB or IV non-small cell lung cancer.
- •Confirmation that the tumor harbours an EGFR mutation known to be associated with EGFR TKI sensitivity (including G719X, exon 19 deletion, L858R, L861Q).
- •Eastern Cooperative Oncology Group performance status of 0 to 2
- •Prior treatment with at least one line of a single agent EGFR TKI (gefitinib, erlotinib, afatinib) and confirmed progressive disease after treatment with EGFR TKI
- •Regardless of treatment sequence between previous chemotherapy and EGFR TKI
- •Regardless of whether they were administered conventional chemotherapy, if therapy were treated with at least one EGFR TKI
- •Subjects who will undergo bronchoscopy/ BAL procedures and sufficient amount of BAL fluid is carefully collected for EGFR mutation analysis.
- •Confirmation that the extracellular vesicles (EV) extracted from bronchoalveolar lavage fluid (BALF) harbour T790M mutation (It can be replaced previous the same result throughout the follow up period before enrollment.)
- •At least one measurable disease (except brain) at baseline according to RECIST version 1.1
- •Female subjects must be postmenopausal (for at least one year), or, if sexually active, be practicing an effective method of birth control (e.g., prescription oral contraceptives, contraceptive injections, intrauterine device, double-barrier method, contraceptive patch, male partner sterilization) before entry and throughout the study; and, for those of childbearing potential, have a negative urinary β-hCG pregnancy test at screening.
- •Male subjects should be willing to use barrier methods which are suitable for sexual partner throughout the study.
- •Subjects must have signed an informed consent document indicating that they understand the purpose of and procedures required for the study and are willing to participate in the study. The subject also must sign and date the consent form before specific procedures or sampling.
- •Adequate organ function as defined by liver, kidney, and hematologic laboratory testing as below
- •Absolute neutrophil count (ANC) ≥ 1500/mm3, Platelet ≥ 100,000 /mm3 Hemoglobin (Hb) ≥ 9.0g/dL
- •Serum creatinine ≤ upper limit of normal (ULN)
- •AST/ALT/ALP ≤ 3 times ULN, Total bilirubin ≤2.0 mg/dL AST/ALT/ALP ≤ 5 times ULN in patients with metastatic lesions to the liver ALP ≤ 5 times ULN in patients with metastatic lesions to the bone
- •Expected survival of at least 12 weeks
排除标准
- •Previous treatment with anticancer therapies, EGFR-TKI, olmutinib (HM61713), or other drugs that target T790M-positive mutant EGFR with sparing of wild-type, Osimertinib (AZD9291), Rociletinib (CO-1686), investigational agent(s) within 30 days prior to the first administration of study drug, radiotherapy
- •Treatment with a potent cytochrome P450 (CYP) 3A4 inhibitors or inducers
- •History of any other malignancy EXCEPTIONS are:
- •adequately treated non-melanoma skin cancer, curatively treated in situ cancer of the cervix, ductal carcinoma in situ (DCIS) of the breast, thyroid cancer
- •other malignancies diagnosed prior to randomisation and treated with no evidence of disease recurrence more than 3 years
- •Any history or presence of clinically relevant cardiovascular abnormalities such as uncontrolled hypertension, congestive heart failure NYHA classification of III or IV, unstable angina or poorly controlled arrhythmia as determined by the investigator. Myocardial infarction within 6 months prior to enrolment. Increased QTc interval > 450 ms on screening ECG
- •Any history of presence of interstitial lung disease
- •Any history or presence of poorly controlled gastrointestinal disorders that could affect the absorption of the trial drug (e.g. Crohn's disease, ulcerative colitis, chronic diarrhea, malabsorption).
- •Ongoing active infection with, hepatitis B virus (infection defined as a positive HbsAg and/ or HBV DNA), hepatitis C virus (infection defined as a positive HCV RNA), or human immunodeficiency virus (HIV) Type 1/2 infection at the time of screening.
- •Known history of hypersensitivity to active or inactive excipients of study drug (olmutinib) or drugs with a similar chemical structure of olmutinib
- •Subjects with galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption
- •Symptomatic or uncontrolled central nervous system (CNS) metastases (Patients are eligible if they have completed their treatment and have recovered from the acute effects of radiation therapy or surgery prior to the start of study medication, have discontinued corticosteroid treatment for these metastases for at least 4 weeks and are neurologically and radiologically stable)
- •Uncontrolled active infectious disease (with the exception of those that are considered to be needed topical antibiotics, however subjects can be enrolled into the study after they complete their treatment)
- •Unable to attend all the study visits or comply with study procedures
- •Patients who had received other investigational product within 30 days prior to the first administration of study drug except for gefitinib, erlotinib, or afatinib
研究组 & 干预措施
Olmutinib
Experimental
Single arm of Olmutinib, staring dose of 800 mg
干预措施: Olmutinib (Drug)
结局指标
主要结局
Objective response rate (ORR)
时间窗: Change from baseline at every 6 weeks until disease progression or withdrawal from study, assessed up to 12 months
defined as the proportion of patients who achieved complete remission(CR) or partial remission(PR) based on RECIST version 1.1
次要结局
- Disease control rate (DCR)(Change from baseline at every 6 weeks until disease progression or withdrawal from study, assessed up to 12 months)
- Progression-free survival (PFS)(Change from baseline at every 6 weeks until disease progression or withdrawal from study, assessed up to 12 months)
研究者
Kye Young Lee
Professor
Konkuk University Medical Center
研究点 (1)
Loading locations...
相似试验
终止
1 期
Olmutinib 600 mg QD in Patients With T790M-positive NSCLC After Treatment With an EGFR-TKINon Small Cell Lung CancerNCT04510415Hanmi Pharmaceutical Company Limited2
已完成
2 期
A phase II study of osimertinib in patients with poor performance status and non-small-cell lung cancerEGFR mutation T790M-positive non-small-cell lung cancernon-small-cell lung cancer, EGFR T790M mutation-positiveJPRN-jRCT1041180081Murakami Haruyasu18
已完成
2 期
Erlotinib in Treating Patients With Locally Advanced or Metastatic Papillary Renal Cell CancerRecurrent Renal Cell CancerStage III Renal Cell CancerStage IV Renal Cell CancerNCT00060307National Cancer Institute (NCI)40
已完成
2 期
Erlotinib in Treating Patients With Unresectable Liver, Bile Duct, or Gallbladder CancerAdult Primary Cholangiocellular CarcinomaAdult Primary Hepatocellular CarcinomaAdvanced Adult Primary Liver CancerCholangiocarcinoma of the Extrahepatic Bile DuctCholangiocarcinoma of the GallbladderLocalized Unresectable Adult Primary Liver CancerRecurrent Adult Primary Liver CancerRecurrent Extrahepatic Bile Duct CancerRecurrent Gallbladder CancerUnresectable Extrahepatic Bile Duct CancerUnresectable Gallbladder CancerNCT00033462National Cancer Institute (NCI)78
已完成
不适用
Efficacy and Safety of Osimertinib for HK Chinese With Metastatic T790M Mutated NSCLC-real World Setting.Non-small Cell Lung CancerNCT03219970AstraZeneca156